Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer

ConclusionThis trial showed the lack of benefits from Sr-89 addition to ZOL for breast cancer patients with painful bone metastases. However, safety and analgesic drug dose reduction were more evident in ZOL  + Sr-89, indicating its potential for pain control. Sr-89 therapy is safe, thus more effective radiopharmaceuticals are anticipated.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research